Table 2.

Toxicities

Patient	CTC Criteria	Grade of AE	Time since Starting Vandetanib (years)	Duration of Hold (days)	Dose Change (mg/m2)
2	Hemorrhage	2	4.75	83
	Weight Loss	2	6.04	0	150 -> 100
5	ALT, SGPT	3	3.83	11
	Weight Loss; Proteinuria; Hypertension	2	5.56	13	100 -> 67
6	Creatinine	2	6.32	699	150 -> 100
	Wound Healing#	N/A	7.22	630*
8	Wound Healing#	N/A	3.47	24
			3.9	33
			4.62	49
9	Patient Preference#	N/A	1.93	2144*	discontinued
10	Vomiting	3	3.9	7
	Abdominal Pain	2
	Constipation	3	5.27	51	150 -> 100
12	Diarrhea	2	3.92	0	150 -> 100
13	Palpitations	2	1.81	28
	Palpitations	2	3.49	112	150 -> 100
	DLCO; Pulmonary other; Pulmonary cysts by CT	2	4	112
	Pregnancy#	N/A	5.57	363*	discontinued
14	Wound Healing#	N/A	1.99	1
			2.05	2
	Wound Healing#	N/A		8
	Oral Hemorrhage	2	2.93	7
16	Supraventricular and nodal arrhythmia	2	0.11	7	150 -> 100
	Hypertension	2	0.15	7
17	Diarrhea	2	0.45	4	100 -> 67

^*Continues to hold at data cutoff,

^#unrelated to therapy